Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 1
2018 1
2019 1
2020 6
2021 6
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
The redox-senescence axis and its therapeutic targeting.
Ngoi NY, Liew AQ, Chong SJF, Davids MS, Clement MV, Pervaiz S. Ngoi NY, et al. Among authors: chong sjf. Redox Biol. 2021 Sep;45:102032. doi: 10.1016/j.redox.2021.102032. Epub 2021 Jun 5. Redox Biol. 2021. PMID: 34147844 Free PMC article. Review.
Noncanonical Cell Fate Regulation by Bcl-2 Proteins.
Chong SJF, Marchi S, Petroni G, Kroemer G, Galluzzi L, Pervaiz S. Chong SJF, et al. Trends Cell Biol. 2020 Jul;30(7):537-555. doi: 10.1016/j.tcb.2020.03.004. Epub 2020 Apr 16. Trends Cell Biol. 2020. PMID: 32307222 Review.
Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies.
Chong SJF, Zhu F, Dashevsky O, Mizuno R, Lai JX, Hackett L, Ryan CE, Collins MC, Iorgulescu JB, Guièze R, Penailillo J, Carrasco R, Hwang YC, Muñoz DP, Bouhaddou M, Lim YC, Wu CJ, Allan JN, Furman RR, Goh BC, Pervaiz S, Coppé JP, Mitsiades CS, Davids MS. Chong SJF, et al. J Clin Invest. 2023 Nov 15;133(22):e170169. doi: 10.1172/JCI170169. J Clin Invest. 2023. PMID: 37751299 Free PMC article.
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
Herbaux C, Kornauth C, Poulain S, Chong SJF, Collins MC, Valentin R, Hackett L, Tournilhac O, Lemonnier F, Dupuis J, Daniel A, Tomowiak C, Laribi K, Renaud L, Roos-Weil D, Rossi C, Van Den Neste E, Leyronnas C, Merabet F, Malfuson JV, Tiab M, Ysebaert L, Ng S, Morschhauser F, Staber PB, Davids MS. Herbaux C, et al. Among authors: chong sjf. Blood. 2021 Jun 24;137(25):3495-3506. doi: 10.1182/blood.2020007303. Blood. 2021. PMID: 33598678 Free article. Clinical Trial.
Breaking through BCL-2 inhibition in CLL.
Chong SJF, Davids MS. Chong SJF, et al. Blood. 2020 Mar 5;135(10):709-711. doi: 10.1182/blood.2019004767. Blood. 2020. PMID: 32135019 Free article. No abstract available.
Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors.
Sklavenitis-Pistofidis R, Lightbody ED, Reidy M, Tsuji J, Aranha MP, Heilpern-Mallory D, Huynh D, Chong SJF, Hackett L, Haradhvala NJ, Wu T, Su NK, Berrios B, Alberge JB, Dutta A, Davids MS, Papaioannou M, Getz G, Ghobrial IM, Manier S. Sklavenitis-Pistofidis R, et al. Among authors: chong sjf. bioRxiv [Preprint]. 2023 Aug 3:2023.08.01.551480. doi: 10.1101/2023.08.01.551480. bioRxiv. 2023. PMID: 37577538 Free PMC article. Preprint.
19 results